|
US6946129B1
(en)
|
1999-06-08 |
2005-09-20 |
Seattle Genetics, Inc. |
Recombinant anti-CD40 antibody and uses thereof
|
|
MX2010005099A
(es)
*
|
2007-11-09 |
2010-05-27 |
Novartis Ag |
Usos de anticuerpos anti-cd40.
|
|
WO2009094391A1
(en)
*
|
2008-01-23 |
2009-07-30 |
Xencor, Inc. |
Optimized cd40 antibodies and methods of using the same
|
|
KR101787768B1
(ko)
|
2009-04-18 |
2017-10-18 |
제넨테크, 인크. |
항-ｃｄ４０ 항체를 사용한 치료에 대한 ｂ-세포 림프종의 반응성 평가를 위한 방법
|
|
PH12012500881A1
(en)
|
2009-12-10 |
2017-07-26 |
Hoffmann La Roche |
Antibodies binding preferentially human csf1r extracellular domain 4 and their use
|
|
CN102918061B
(zh)
|
2010-03-05 |
2016-06-08 |
霍夫曼-拉罗奇有限公司 |
针对人csf-1r的抗体及其用途
|
|
CA2789076C
(en)
|
2010-03-05 |
2017-11-21 |
F. Hoffmann-La Roche Ag |
Antibodies against human colony stimulating factor-1 receptor and uses thereof
|
|
HUE065915T2
(hu)
|
2011-03-11 |
2024-06-28 |
Beth Israel Deaconess Medical Ct Inc |
Anti-CD40 antitestek és alkalmazásaik
|
|
CN113461819B
(zh)
|
2011-04-29 |
2024-01-02 |
埃派斯进有限公司 |
抗-cd40抗体及其使用方法
|
|
BR112014012624A2
(pt)
|
2011-12-15 |
2018-10-09 |
F Hoffmann-La Roche Ag |
anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
|
|
AR090263A1
(es)
*
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
|
AU2013337903B2
(en)
*
|
2012-10-30 |
2018-08-16 |
Apexigen, Inc. |
Anti-CD40 antibodies and methods of use
|
|
WO2014089177A2
(en)
|
2012-12-04 |
2014-06-12 |
Massachusetts Institute Of Technology |
Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
|
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
|
US9603927B2
(en)
*
|
2014-02-28 |
2017-03-28 |
Janssen Biotech, Inc. |
Combination therapies with anti-CD38 antibodies
|
|
EP3122779B1
(en)
|
2014-03-24 |
2019-05-22 |
Cancer Research Technology Limited |
Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof
|
|
MX386886B
(es)
|
2014-09-09 |
2025-03-12 |
Janssen Biotech Inc |
Combinación de anticuerpos anti-cd38 y ácido todo-trans retinoico para usarse en terapias.
|
|
CA2963720C
(en)
*
|
2014-10-29 |
2024-05-14 |
Seattle Genetics, Inc. |
Dosage and administration of non-fucosylated anti-cd40 antibodies
|
|
AU2015358615B2
(en)
|
2014-12-04 |
2021-08-05 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute myeloid leukemia
|
|
MX389805B
(es)
|
2015-05-20 |
2025-03-11 |
Janssen Biotech Inc |
Anticuerpos anti-cd38 para el tratamiento de amiloidosis de cadena ligera y otras enfermedades malignas hematológicas positivas para cd38.
|
|
AU2016282674B2
(en)
|
2015-06-22 |
2022-01-13 |
Janssen Biotech, Inc. |
Combination therapies for heme malignancies with anti-CD38 antibodies and survivin inhibitors
|
|
US20170044265A1
(en)
|
2015-06-24 |
2017-02-16 |
Janssen Biotech, Inc. |
Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
|
|
WO2017040932A1
(en)
|
2015-09-04 |
2017-03-09 |
Primatope Therapeutics Inc. |
Humanized anti-cd40 antibodies and uses thereof
|
|
US10781261B2
(en)
|
2015-11-03 |
2020-09-22 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-CD38 antibodies and their uses
|
|
DK3827845T3
(da)
|
2015-11-03 |
2022-05-23 |
Janssen Biotech Inc |
Subkutane formuleringer af anti-cd38-antistoffer og anvendelser deraf
|
|
US10918627B2
(en)
|
2016-05-11 |
2021-02-16 |
Massachusetts Institute Of Technology |
Convergent and enantioselective total synthesis of Communesin analogs
|
|
JP2019527678A
(ja)
|
2016-06-28 |
2019-10-03 |
ユーエムセー・ユトレヒト・ホールディング・ベー・フェー |
ＣＤ３８に特異的に結合する抗体によるＩｇＥ媒介疾患の治療
|
|
CN109790220A
(zh)
|
2016-08-25 |
2019-05-21 |
豪夫迈·罗氏有限公司 |
与巨噬细胞激活剂组合的抗csf-1r抗体的间歇给药
|
|
CN110072553B
(zh)
|
2016-12-22 |
2023-09-15 |
豪夫迈·罗氏有限公司 |
在抗pd-l1/pd1治疗失败之后抗csf-1r抗体与抗pd-l1抗体组合对肿瘤的治疗
|
|
US10640508B2
(en)
|
2017-10-13 |
2020-05-05 |
Massachusetts Institute Of Technology |
Diazene directed modular synthesis of compounds with quaternary carbon centers
|
|
JP2021502961A
(ja)
|
2017-10-31 |
2021-02-04 |
ヤンセン バイオテツク，インコーポレーテツド |
高リスク多発性骨髄腫の治療方法
|
|
CN112638375A
(zh)
|
2018-06-15 |
2021-04-09 |
旗舰创业创新五公司 |
通过后细胞信号传导因子的调节来增加免疫活性
|
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
|
JP2023509359A
(ja)
|
2019-12-17 |
2023-03-08 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
鉄依存性細胞分解の誘導物質との併用抗癌療法
|
|
JP2023532339A
(ja)
|
2020-06-29 |
2023-07-27 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
サノトランスミッションを促進するためにエンジニアリングされたウイルス及び癌の処置におけるそれらの使用
|
|
JP2024512669A
(ja)
|
2021-03-31 |
2024-03-19 |
フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド |
タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
|
|
WO2022266496A1
(en)
*
|
2021-06-17 |
2022-12-22 |
Parker Institute For Cancer Immunotherapy |
Methods of treating kras mutation subtypes with cd40 agonist
|
|
US20240316104A1
(en)
|
2021-06-29 |
2024-09-26 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
|
US12234294B2
(en)
|
2021-11-05 |
2025-02-25 |
Kiniksa Pharmaceuticals, Gmbh |
Pharmaceutical composition of a humanized anti-CD40 antibody
|
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
|
WO2024151687A1
(en)
|
2023-01-09 |
2024-07-18 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|